LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Orbital ATK, Inc. (“Orbital” or the “Company”) (NYSE: OA) concerning possible violations of federal securities laws between June 1, 2015 and August 9, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the October 11, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that during the Class Period, Orbital made materially false and misleading statements, and/or failed to disclose: that Orbital lacked effective control over financial reporting; that the Company failed to record an anticipated loss on a $2.3 billion long-term contract with the U.S. Army after the loss became evident in 2015, as required by generally accepted accounting principles; and that as a result of the above, Orbital’s public statements were materially false and misleading at all relevant times.

On August 10, 2016, the Company announced that it would miss its SEC Form 10-Q filing deadline for the most recent quarter and that several previous financial statements are no longer reliable due to misstatements relating to the above-mentioned contract with the U.S. army. When this information was released to the public, shares of Orbital fell in value, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444588

LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Flowers Foods, Inc. (“Flowers Foods” or the “Company”) (NYSE: FLO) concerning possible violations of federal securities laws between February 7, 2013 and August 10, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the October 11, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that during the Class Period, the Company issued false and misleading statements and/or failed to disclose that: Flowers Foods was improperly classifying employees as independent contractors; that the misclassification exposed Flowers Foods to legal liability and/or negative regulatory action; that proper classification would have a negative impact on Flowers Foods’ operations; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.

On August 10, 2016, the Company announced that the U.S. Department of Labor scheduled a compliance review of Flowers Foods under the Fair Labor Standards Act. After the market closed that day, the Company issued a press release announcing disappointing Q2 2016 financial results. When this information was disclosed to the public, shares of Flowers Foods decreased in value, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444587

LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Embraer S.A. (“Embraer” or the “Company”) (NYSE: ERJ) concerning possible violations of federal securities laws between April 16, 2012 and July 28, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the October 7, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that during the Class Period, the Company made false and misleading statements and/or failed to disclose material facts, specifically: that it paid bribes to Dominican Republic officials to secure contracts for aircraft sales; that Embraer’s President and CEO Frederico Curado had knowledge of the bribe; that the fallout from this misconduct would cost Embraer hundreds of millions of dollars; and as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. In June 2016, the Company stated that its CEO Frederico Curado would be stepping down. On July 29, 2016, Embraer announced a loss of $99.4 million for the quarter after setting aside $200 million in connection with a U.S. Foreign Corrupt Practices Act probe that it was negotiating with the U.S. Department of Justice since May 2015. The Company also reduced 2016 guidance for its executive jet business. When this information was disclosed to the public, Embraer shares dropped in value, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444586

IRVINE, CA / ACCESSWIRE / August 31, 2016 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit has been filed against CytRx Corporation (“CytRx” or the “Company”) (Nasdaq: CYTR). Investors who purchased or otherwise acquired shares between November 18, 2014 and July 11, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the September 23, 2016 lead plaintiff motion deadline.

If you purchased CytRx shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that the Company made materially false and misleading statements and/or failed to disclose that: the clinical hold placed on the Phase 3 trial of aldoxorubicin would prevent sufficient follow-up for patients involved in the study; that almost half of the patients would be excluded from the progression free survival evaluation; CytRx would like conduct a second analysis; that the results of the trial could be affected or approval of aldoxorubicin could be delayed; and that as a result of the above, the Company’s statements were false and misleading and/or lacked a reasonable basis at all relevant times. When this news was disclosed to the public, shares of CytRx fell in value, causing investors harm.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 444585

IRVINE, CA / ACCESSWIRE / August 31, 2016 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit has been filed against K12, Inc. (“K12” or the “Company”) (NYSE: LRN). Investors who purchased or otherwise acquired shares between November 7, 2013 and October 27, 2015 (the “Class Period”), are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline.

If you purchased K12 shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, K12 issued false and misleading statements and/or failed to disclose: that the Company published misleading advertisements about students’ academic progress, parent satisfaction, graduates’ eligibility for admission into the University of California and California State University, class sizes, the individualized and flexible nature of K12’s instruction, hidden costs, and the quality of the materials provided to students; that the Company submitted inflated student attendance numbers to the California Department of Education in order to receive additional funding; that K12 was open to potential civil and criminal liability due to these practices; that K12 would likely be forced to end these practices, which would have a negative impact on its operations and prospects; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this information was disclosed to the public, shares of K12 fell in value, causing investors harm.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 444584

LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. (“Keryx” or the “Company”) (Nasdaq: KERX) concerning possible violations of federal securities laws between February 25, 2016 and August 1, 2016 (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the October 3, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that during the Class Period, Keryx made false and misleading statements and/or failed to disclose: that Keryx was experiencing production-related difficulties in converting API to finished drug product; that the issue was resulting in decreased production yields of finished drug product; that the Company exhausted its reserve of finished drug product; and as a result of the above, Keryx’s statements about its business, operations and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444583

LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Emergent BioSolutions, Inc. (“Emergent” or the “Company”) (NYSE: EBS) concerning possible violations of federal securities laws between January 11, 2016 and June 21, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm before the September 19, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, the Company issued materially false and misleading statements about its business and financial prospects, specifically relating to future lucrative contract renewals and demand from the U.S. government for its anthrax vaccine BioThrax. These statements caused the Company’s common stock to trade at artificially inflated prices, which certain defendants were able to sell. On June 22, 2016, Emergent announced that the U.S. government issued notices that it would be purchasing fewer doses than investors were led to believe, and that when newer and faster next-generation anthrax vaccines are developed and approved, the Company would lose its procurement contract exclusivity. When this information was released to the public, shares of Emergent fell in value, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444582

LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit was filed against Eaton Corporation plc (“Eaton” or the “Company”) (NYSE: ETN) concerning possible violations of federal securities laws between November 13, 2013 and July 28, 2014 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the September 23, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, Eaton issued false and misleading statements about the Company’s ability to divest its automobile-part manufacturing business. Since 2008, the Company shifted away from its vehicle business and expanded its electrical component businesses. In 2012, Eaton merged with Irish-headquartered Cooper Industries plc, which reincorporated the Company in Ireland. After the merger, Eaton executives assured investors of the continued feasibility of divesting the automobile-part manufacturing business on a tax-free basis. This kept the Eaton stock price artificially inflated. On July 29, 2014, Eaton’s CEO Alexander M. Cutler informed investors that the Company could not feasibly divest the automobile-part business until late 2017 because of tax law restrictions related to the merger. Mr. Cutler also revealed that the Company was “well aware” of these restrictions all along. When this news was released to the public, shares of Eaton fell in value, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444581

LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Fiat Chrysler Automobiles N.V. (“Fiat” or the “Company”) (NYSE: FCAU) concerning possible violations of federal securities laws between October 29, 2014 and July 18, 2016 (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the September 27, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that throughout the Class Period, Fiat made false and misleading statements and/or failed to disclose material facts about its business and operations. Specifically, the Company misrepresented its growth by purposefully inflating the vehicle sales numbers of its U.S. subsidiary FCA US LLC and falsely touting its streak of U.S. monthly vehicle sales growth (on a year-over-year basis). On January 12, 2016, a civil lawsuit was filed against Fiat, alleging that the Company had inflated the number of year-over-year sales reported. On January 15, 2016, the Company filed a Form 6-K acknowledging that a lawsuit had been filed against FCA US LLC. When this information was released to the public, Fiat shares dropped in value significantly, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444580

IRVINE, CA / ACCESSWIRE / August 31, 2016 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit has been filed against Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (Nasdaq: TKAI). Investors who purchased or otherwise acquired shares between June 24, 2015 and July 25, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the September 30, 2016 lead plaintiff motion deadline.

If you purchased shares of Tokai during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Tokai made false and misleading statements and/or failed to disclose that: there were significant structural problems with the trial design for its Phase 3 galeterone study, ARMOR3-SV; that ARMOR3-SV was unlikely to succeed in meeting its primary endpoint; the commercialization of galeterone was less likely than investors were led to believe; and as a result of the above, Tokai’s statements about its business, operations, and prospects were false and misleading at all relevant times.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 444579